CYduct Diagnostics, Inc.
CYDX · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -16.3% | -29.2% | 26.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 66.2% | 67% | 69.9% | 67.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -513.8% | -448.5% | -372.6% | -429.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -585.1% | -494.8% | -396.1% | -447.1% |
| EPS | -0.079 | -0.08 | -0.093 | -0.082 |
| % Growth | 1.7% | 13.3% | -13.2% | – |
| EPS Diluted | -0.079 | -0.08 | -0.093 | -0.082 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -513.8% | -448.5% | -369.7% | -177.5% |